Correlation Analysis Among the Level of IL-35, Microvessel Density, Lymphatic Vessel Density, and Prognosis in Non-Small Cell Lung Cancer

Overview

Journal Clin Transl Sci

Specialties Biomedical Engineering
General Medicine

Date 2020 Oct 13

PMID 33048433

Citations 14

Authors

Tenglong Zhang

Jing Nie

Xiaojiang Liu

Zenglei Han

Ning Ding

Kai Gai

Yang Liu

Ling Chen

ChengYe Guo

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to determine the expression of IL-35 and the lymphatic vessel density (LVD) and microvessel density (MVD) in the pathological tissues from patients with non-small cell lung cancer (NSCLC) and to analyze their correlation with other common clinical prognostic factors, as well as patients' overall survival and progression-free survival. We analyzed the pathological characteristics of 130 patients with NSCLC and determined the IL-35 expression, MVD, and LVD changes in the pathological tissues by immunohistochemistry. The results showed that IL-35 expression was significantly correlated with tumor differentiation, lymph node metastasis, T staging, LVD, and MVD (P < 0.05) but was not associated with age, sex, smoking, and other factors. Univariate analysis of risk models showed that age, lymph node metastasis, T stage, and high IL-35 expression, LVD, and MVD were significantly associated with NSCLC prognosis (P < 0.05), whereas sex, smoking, and high differentiation were not correlated with prognosis. Multivariate analysis of the proportional risk model showed that the IL-35 expression, lymph node metastasis, high LVD, and high MVD were significantly correlated with NSCLC prognosis (P < 0.05). In conclusion, IL-35, MVD, and LVD may be independent prognostic markers. In addition, IL-35 might represent a promising clinical drug target for the treatment of NSCLC.

Citing Articles

Significance of Tumor Microvasculature in the Tumor Microenvironment in Adenocarcinoma with EGFR Common Mutations.

Matsudo K, Takada K, Hashinokuchi A, Nagano T, Kinoshita F, Akamine T Ann Surg Oncol. 2025; 32(4):3031-3039.

PMID: 39812916 DOI: 10.1245/s10434-024-16806-4.

High microvessel and lymphatic vessel density predict poor prognosis in patients with esophageal squamous cell carcinoma.

Qi L, Xie Y, Wang W, Liu J, Yang K, Chen K PeerJ. 2024; 12:e18080.

PMID: 39351370 PMC: 11441385. DOI: 10.7717/peerj.18080.

Upregulation of TCPTP in Macrophages Is Involved in IL-35 Mediated Attenuation of Experimental Colitis.

Zhang B, Sun C, Zhu Y, Qin H, Kong D, Zhang J Mediators Inflamm. 2024; 2024:3282679.

PMID: 38962170 PMC: 11221972. DOI: 10.1155/2024/3282679.

Estimation of the tissue and serum levels of IL-35 in Mycosis fungoides: a case-control study.

Elmasry M, Obaid Y, El-Samanoudy S, Nour Z, Doss S Arch Dermatol Res. 2024; 316(7):349.

PMID: 38850434 PMC: 11162372. DOI: 10.1007/s00403-024-03115-9.

Negative impact of ratio of the microvascular area to tumor area on the response to EGFR-TKI in non-small cell lung cancer with an mutation.

Anai M, Saruwatari K, Imamura K, Fujino K, Jodai T, Sakata S J Thorac Dis. 2024; 16(2):1151-1160.

PMID: 38505064 PMC: 10944797. DOI: 10.21037/jtd-23-1723.

References

Hu W, Liu Y, Chen J . Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer. Oncotarget. 2017; 8(15):25046-25054. PMC: 5421908. DOI: 10.18632/oncotarget.15337. View

Rafei H, El-Bahesh E, Finianos A, Nassereddine S, Tabbara I . Immune-based Therapies for Non-small Cell Lung Cancer. Anticancer Res. 2017; 37(2):377-387. DOI: 10.21873/anticanres.11330. View

Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M . The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2004; 92(1):131-9. PMC: 2361730. DOI: 10.1038/sj.bjc.6602258. View

Sundov Z, Tomic S, Alfirevic S, Sundov A, capkun V, Nincevic Z . Prognostic value of MVD, LVD and vascular invasion in lymph node-negative colon cancer. Hepatogastroenterology. 2013; 60(123):432-8. DOI: 10.5754/hge12826. View

Collison L, Chaturvedi V, Henderson A, Giacomin P, Guy C, Bankoti J . IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010; 11(12):1093-101. PMC: 3008395. DOI: 10.1038/ni.1952. View

Deben C, Van den Bossche J, Van Der Steen N, Lardon F, Wouters A, Op de Beeck K . Deep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants. Tumour Biol. 2017; 39(2):1010428317694327. DOI: 10.1177/1010428317694327. View

Chen L, Qin Y, Zhang T, Ding N, Chen Y, Zhang Z . Clinical significance of cancer-associated fibroblasts and their correlation with microvessel and lymphatic vessel density in lung adenocarcinoma. J Clin Lab Anal. 2019; 33(4):e22832. PMC: 6528563. DOI: 10.1002/jcla.22832. View

Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N . Cancer survival in China, 2003-2005: a population-based study. Int J Cancer. 2014; 136(8):1921-30. DOI: 10.1002/ijc.29227. View

Gu X, Tian T, Zhang B, Liu Y, Yuan C, Shao L . Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer. Tumour Biol. 2014; 36(4):2651-6. DOI: 10.1007/s13277-014-2887-8. View

10.

Hahn H, Shahsafaei A, Odze R . Vascular and lymphatic properties of the superficial and deep lamina propria in Barrett esophagus. Am J Surg Pathol. 2008; 32(10):1454-61. DOI: 10.1097/PAS.0b013e31817884fd. View

11.

Moreira A, Thornton R . Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing. Clin Lung Cancer. 2012; 13(5):334-9. DOI: 10.1016/j.cllc.2012.01.004. View

12.

Korpanty G, Graham D, Vincent M, Leighl N . Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol. 2014; 4:204. PMC: 4127527. DOI: 10.3389/fonc.2014.00204. View

13.

Vignali D, Kuchroo V . IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012; 13(8):722-8. PMC: 4158817. DOI: 10.1038/ni.2366. View

14.

Wang Y, Mao Y, Zhang J, Shi G, Cheng L, Lin Y . IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells. J Cell Mol Med. 2017; 22(2):1014-1025. PMC: 5783847. DOI: 10.1111/jcmm.13428. View

15.

Trebeschi S, Drago S, Birkbak N, Kurilova I, Calin A, Delli Pizzi A . Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol. 2019; 30(6):998-1004. PMC: 6594459. DOI: 10.1093/annonc/mdz108. View

16.

Zhao J, Han Y, Li J, Chai R, Bai C . Prognostic value of in non-small cell lung cancer. Oncol Lett. 2019; 17(3):3233-3240. PMC: 6396221. DOI: 10.3892/ol.2019.10012. View

17.

Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. DOI: 10.3322/caac.21208. View

18.

Long J, Zhang X, Wen M, Kong Q, Lv Z, An Y . IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem Biophys Res Commun. 2012; 430(1):364-9. DOI: 10.1016/j.bbrc.2012.11.004. View

19.

VanderLaan P, Rangachari D, Mockus S, Spotlow V, Reddi H, Malcolm J . Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer. 2017; 106:17-21. PMC: 5351777. DOI: 10.1016/j.lungcan.2017.01.011. View